According to a recent LinkedIn post from Xeltis, the company’s clinical team visited the dialysis clinic at Zemun Hospital in Belgrade, Serbia, which is participating in the next phase of the aXess clinical trials. The post notes that the Zemun team, led by Prof. Tamara Jemcov, has implanted four patients with Xeltis’ novel ETR hemodialysis conduit, with all four reportedly doing well on dialysis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that this site is contributing to the expansion of clinical evidence and access for the aXess technology across additional locations and EU countries. For investors, successful early outcomes at a new European center may signal progress toward broader clinical adoption, a potential de-risking of the technology, and a foundation for future reimbursement discussions and commercial scaling in the dialysis vascular access market.
By highlighting collaboration with a nephrologist who also serves as President of the Vascular Access Society, the post points to growing engagement with influential clinicians in the vascular access field. This could support Xeltis’ positioning in a competitive hemodialysis access segment, where credible clinical partners and positive real-world data are often key drivers of long-term market penetration and valuation upside.